Introducing Cytology-Based Theranostics in Oral Squamous Cell Carcinoma: A Pilot Program
作者： Anna Patrikidou , Rosalia Maria Valeri , Kyriaki Kitikidou , Charikleia Destouni , Konstantinos Vahtsevanos
DOI: 10.1007/S12253-015-0017-6
关键词:
摘要: We aimed to evaluate the feasibility and reliability of brush cytology in biomarker expression profiling oral squamous cell carcinomas within concept theranostics, correlate this profile with patient measurable outcomes. Markers representative prognostic gene changes carcinoma was selected. These markers were also selected involve pathways for which commercially available or investigational agents exist clinical application. A set 7 analysed by immunocytochemistry on archival primary tumour material 99 patients. confirmed technique carcinomas. Furthermore, our results affirm significance epidermal growth factor receptor (EGFR) family angiogenic pathway carcinoma, confirming their interest targeted therapy. Brush appears feasible applicable according sample availability.
springer.com
sci-hub.se 参考文章(54)
D Stramazzotti, M Messi, T Pieramici, G Goteri, G Ascani, C Rubini, A Filosa, P Balercia, L Lupi, Angiogenesis in oral squamous cell carcinoma. Acta Otorhinolaryngologica Italica. ,vol. 25, pp. 13- 17 ,(2005)
Frauke Devens, Christa Flechtenmacher, Franz X. Bosch, Stefan Joos, Axel Benner, Peter Lichter, Christof Hofele, Kolja Freier, Distinct site-specific oncoprotein overexpression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Research. ,vol. 23, pp. 3971- 3977 ,(2003)
D Pirici, Cl Mărgăritescu, Cristiana Simionescu, A Stepan, The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC). Romanian Journal of Morphology and Embryology. ,vol. 52, pp. 985- 993 ,(2011)
Michael Ryott, Linda Marklund, Darawalee Wangsa, Göran Elmberger, Eva Munck-Wikland, Cyclooxygenase‐2 expression in oral tongue squamous cell carcinoma Journal of Oral Pathology & Medicine. ,vol. 40, pp. 385- 389 ,(2011) , 10.1111/J.1600-0714.2010.00992.X
Martin Früh, Miklos Pless, EGFR IHC score for selection of cetuximab treatment: Ready for clinical practice? Translational lung cancer research. ,vol. 1, pp. 145- 146 ,(2012) , 10.3978/J.ISSN.2218-6751.2012.03.01
Joel L. Schwartz, Suchismita Panda, Craig Beam, Laura E. Bach, Guy R. Adami, RNA from brush oral cytology to measure squamous cell carcinoma gene expression. Journal of Oral Pathology & Medicine. ,vol. 37, pp. 70- 77 ,(2007) , 10.1111/J.1600-0714.2007.00596.X
Benjamin D. Smith, Grace L. Smith, Darryl Carter, Clarence T. Sasaki, Bruce G. Haffty, Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. Journal of Clinical Oncology. ,vol. 18, pp. 2046- 2052 ,(2000) , 10.1200/JCO.2000.18.10.2046
Francesca Angiero, Rachele Del Sordo, Enrico Dessy, Elisa Rossi, Angiola Berenzi, Michele Stefani, Angelo Sidoni, Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters? Journal of Oral Pathology & Medicine. ,vol. 37, pp. 145- 150 ,(2007) , 10.1111/J.1600-0714.2007.00603.X
Ricardo L. C. Albuquerque Júnior, Márcia C. C. Miguel, Antonio L. L. Costa, Lélia B. Souza, Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma International Journal of Experimental Pathology. ,vol. 84, pp. 259- 265 ,(2004) , 10.1111/J.0959-9673.2004.00361.X
Jean-Pascal H Machiels, Robert I Haddad, Jérôme Fayette, Lisa F Licitra, Makoto Tahara, Jan B Vermorken, Paul M Clement, Thomas Gauler, Didier Cupissol, Juan José Grau, Joël Guigay, Francesco Caponigro, Gilberto de Castro, Luciano de Souza Viana, Ulrich Keilholz, Joseph M del Campo, Xiuyu Julie Cong, Eva Ehrnrooth, Ezra E W Cohen, Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial The Lancet Oncology. ,vol. 16, pp. 583- 594 ,(2015) , 10.1016/S1470-2045(15)70124-5